Docetaxel in Non-Small Cell Lung Cancer: A Multi-Centre Real-World Evidence Analysis in the Immunotherapy Era.

Docetaxel has been a standard second-line or later (2L+) treatment for advanced non-small cell lung cancer (NSCLC) for more than two decades and remains recommended in current treatment algorithms. However, real-world outcomes in the era of immune checkpoint inhibitors (ICI) are limited. This multicenter retrospective study included patients with advanced NSCLC treated with 2L+ docetaxel monotherapy between January 2011 and December 2020. The primary endpoint was median overall survival (mOS) from docetaxel initiation. Subgroup analyses were conducted to identify predictors of OS. A total of 285 patients were analyzed. Median age was 62 years; 43% female, 75% ECOG performance status (PS) 0-1, and 65% adenocarcinoma. Molecular alterations included EGFR (20%) and KRAS (15%). PD-L1 status was available in 66% of patients. Median docetaxel exposure was three cycles, administered as 2L (48%), 3L (35%), or 4L+ (17%). Prior therapies included chemotherapy (96%), ICI (38%), targeted therapy (21%), and chemo-immunotherapy (10%). mOS was 6.5 months (95% CI, 5.9-7.3). On multivariate analysis, KRAS alteration (HR 0.59; 95% CI 0.37-0.94;